Ping Yu

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 529 citations

Medicine, Oncology, Pharmacology +10

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Qun Wang, Weimin Mao, Lin Wu et al. · Journal of Clinical Oncology · 2020 · 279 citations · Full text

Medicine, Oncology, Pharmacology +15

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

Yuankai Shi, Junling Li, Shucai Zhang et al. · PLoS ONE · 2015 · 205 citations · Full text

Medicine, Molecular Medicine, Oncology +14

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Si‐Yang Liu, Hua Bao, Qun Wang et al. · Nature Communications · 2021 · 75 citations · Full text

Medicine, Molecular Genetics, Oncology +15

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Junjie Xi, Wen‐Zhao Zhong, Weimin Mao et al. · Journal of Thoracic Oncology · 2018 · 73 citations

Pharmacy, Pharmacotherapy, Precision Oncology +11